A PHASE 1B DOSE-RANGING STUDY OF 4 WEEKS OF PEG-INTERFERON (IFN) LAMBDA (PEG-RIL-29) IN COMBINATION WITH RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION

被引：0
|
作者：
Muir, Andrew [1 ]
Shiffman, Mitchell L. [2 ]
Zaman, Atif [3 ]
Yoffe, Boris [4 ]
Lopez-Talavera, Juan Carlos [5 ]
Souza, Sherri [6 ]
Hausman, Diana F. [6 ]
Lawitz, Eric [7 ]
机构：
[1] Duke Univ, Durham, NC USA
[2] VCU Med Ctr, Richmond, VA USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Bristol Myers Squibb Co, New York, NY 10154 USA
[6] ZymoGenetics Inc, Seattle, WA USA
[7] Alamo Med Res, San Antonio, TX USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1591
引用
收藏
页码：1039A / 1040A
页数：2
相关论文
共 50 条
  • [11] Meta-Analysis: Sustained Virologic Response (SVR) in Asian Patients With Infection With Hepatitis C Virus Genotype 6 (HCV-6) Versus Genotype 1 (HCV-1) Treated With Pegylated Interferon and Ribavirin (PEG IFN+RBV) for 48 Weeks
    Nguyen, Nghia
    McCormack, Shelley A.
    Yee, Brittany E.
    Vutien, Philip
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2014, 146 (05) : S921 - S922
  • [12] PEGYLATED INTERFERON LAMBDA (PEG-IFN-λ) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12
    Muir, Andrew J.
    Lawitz, Eric
    Ghalib, Reem H.
    Sussman, Norman L.
    Anderson, Frank
    Everson, Gregory T.
    Jacobson, Ira M.
    Lopez-Talavera, Juan Carlos
    Hillson, Jan L.
    Gray, Todd E.
    Fontana, David
    Ramos, Eleanor L.
    Rodriguez-Torres, Maribel
    HEPATOLOGY, 2010, 52 (04) : 715A - 716A
  • [13] Erythropoictic response to anemia is decreased in patients infected with hepatitis C virus (HCV) receiving combination ribavirin and pegylated interferon (RBV/PEG-IFN) therapy
    Balan, V
    Wu, GY
    Muir, AJ
    Keeffe, EB
    Bowers, PJ
    GASTROENTEROLOGY, 2003, 124 (04) : A751 - A751
  • [14] Meta-Analysis: Sustained Virologic Response (SVR) in Patients With Infection With Hepatitis C Virus Genotype 5 (HCV-5) Versus Genotype 1 (HCV-1) and HCV Genotype 2/3 (HCV-2/3) Treated With Interferon (IFN) or Pegylated Interferon and Ribavirin (PEG IFN plus RBV)
    Devaki, Pardha
    Jencks, David S.
    Nangia, Sharad
    Marupakula, Vidyasagargoud
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2014, 146 (05) : S981 - S982
  • [15] Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C
    Atsukawa, Masanori
    Tsubota, Akihito
    Shimada, Noritomo
    Abe, Hiroshi
    Kondo, Chisa
    Itokawa, Norio
    Nakagawa, Ai
    Iwakiri, Katsuhiko
    Kawamoto, Chiaki
    Aizawa, Yoshio
    Sakamoto, Choitsu
    DIGESTIVE AND LIVER DISEASE, 2014, 46 (08) : 738 - 743
  • [16] Reversible alopecia universalis secondary to PEG-interferon α-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection
    Kartal, Elif Doyuk
    Alpat, Saygin Nayman
    Ozgunes, Ilhan
    Usluer, Gaye
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2007, 19 (09) : 817 - 820
  • [17] A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION
    Lawitz, E.
    Jacobson, I.
    Godofsky, E.
    Foster, G. R.
    Flisiak, R.
    Bennett, M.
    Ryan, M.
    Hinkle, J.
    Simpson, J.
    McHutchison, J.
    Oldach, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S181 - S181
  • [18] PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO PEGYLATED INTERFERON ALPHA (PEG-IFN alpha) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1
    Antonov, Krasimir
    Jelev, Deian
    Ivanova, A.
    Krastev, Zahariy
    JOURNAL OF IMAB, 2011, 17 (01): : 197 - 199
  • [19] THE PREDICTIVE MODEL FOR SUSTAINED VIRAL RESPONSE IN PEG-INTERFERON AND RIBAVIRIN THERAPY FOR HEPATITIS C VIRUS GENOTYPE 1B PATIENTS IS A USEFUL MARKER FOR DETERMINE CONTINUATION AND CESSATION OF THE THERAPY
    Tada, Shinichiro
    Saito, Hidetsugu
    Ebinumo, Hirotoshi
    Oiiro, Keisuke
    Yornagishi, Yoshiyuki
    Hibi, Toshifumi
    HEPATOLOGY, 2008, 48 (04) : 885A - 885A
  • [20] Treatment and outcome of genotype 4 chronic hepatitis C patients with Peg-interferon alfa 2b and ribavirin in the clinical setting in Germany
    Zehnter, E.
    Hueppe, D.
    Manns, M. P.
    Mauss, S.
    Zankel, M.
    LIVER INTERNATIONAL, 2006, 26 : 77 - 77
12345